ReviewCurrent topics in medicinal chemistry2014
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.
Review in Current topics in medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Design of a chimeric glycosyltransferase OleD for the site-specific O-monoglycosylation of 3-hydroxypyridine in nosiheptide.Microbial biotechnology · 2023Article
- Synthesis and evaluation of phenylimidazole FabK inhibitors as new Anti-C. Difficile agents.Bioorganic & medicinal chemistry · 2023Article
- Alimentary and Pharmaceutical Approach to Natural Antimicrobials againstFoods (Basel, Switzerland) · 2021Review
- Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.Frontiers in chemistry · 2021Review
- Small-Molecule Inhibition of theACS chemical biology · 2019Article
- Recent advances in the treatment ofInfection and drug resistance · 2019Article
- Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile.ChemMedChem · 2018Article
- Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci.International journal of antimicrobial agents · 2018Article
- Novel FR-900493 Analogues That Inhibit the Outgrowth ofACS omega · 2018Article
- Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.Journal of clinical microbiology · 2017Review
- Review
- Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD.Journal of visualized experiments : JoVE · 2016Article
- Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Cold Spring Harbor perspectives in medicine · 2016Review
- Antibacterial and Synergistic Activity of Pentacyclic Triterpenoids Isolated from Alstonia scholaris.Molecules (Basel, Switzerland) · 2016Article
- Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.The Journal of antimicrobial chemotherapy · 2015Article
- Clostridium difficile drug pipeline: challenges in discovery and development of new agents.Journal of medicinal chemistry · 2015Review
- Resistance-resistant antibiotics.Trends in pharmacological sciences · 2014Review
- Computational medicinal chemistry role in clinical pharmacy education: Ingavirin for coronavirus disease 2019 (COVID-19) discovery model.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Clostridium difficile is an anaerobic, Gram-positive pathogen that causes C. difficile infection, which results in significant morbidity and mortality. The incidence of C. difficile infection in developed countries has become increasingly high due to the emergence of newer epidemic strains, a growing elderly population, extensive use of broad spectrum antibiotics, and limited therapies for this diarrheal disease. Because treatment options currently available for C. difficile infection have some drawbacks, including cost, promotion of resistance, and selectivity problems, new agents are urgently needed to address these challenges. This review article focuses on two parts: the first part summarizes current clinical treatment strategies and agents under clinical development for C. difficile infection; the second part reviews newly reported anti-difficile agents that have been evaluated or reevaluated in the last five years and are in the early stages of drug discovery and development. Antibiotics are divided into natural product inspired and synthetic small molecule compounds that may have the potential to be more efficacious than currently approved treatments. This includes potency, selectivity, reduced cytotoxicity, and novel modes of action to prevent resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.